Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response. 1978

R M Post, and R H Gerner, and J S Carman, and J C Gillin, and D C Jimerson, and F K Goodwin, and W E Bunney

Piribedil, a compound that stimulates dopamine receptors in a relatively specific fashion, was administered to 11 hospitalized depressed patients. The dopamine agonist significantly decreased rapid eye movement (REM) sleep and percent REM sleep and increased REM latency. Piribedil decreased the probenecid-induced accumulation of the dopamine metabolite homovanillic acid (HVA) in CSF. A range of mild to moderate antidepressant effects was noted; one patient worsened and one developed recurrent manic episodes. The degree of improvement in depression was negatively correlated with pretreatment values of HVA in CSF (r = -.66, P less than .05). These data suggest that the heterogeneity of clinical response may be related to biological differences in depressed patients and that those with low initial dopaminergic function respond best to increased dopamine receptor stimulation.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010648 Phenylacetates Derivatives of phenylacetic acid. Included under this heading are a variety of acid forms, salts, esters, and amides that contain the benzeneacetic acid structure. Note that this class of compounds should not be confused with derivatives of phenyl acetate, which contain the PHENOL ester of ACETIC ACID. Benzeneacetates,Benzeneacetic Acids,Phenylacetic Acids,Acids, Benzeneacetic,Acids, Phenylacetic
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D010891 Piribedil A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist. Piribendyl,ET-495,EU-4200,Piribedil Hydrochloride,Piribedil Mesylate,Piribedil Mono-hydrochloride,Trivastal,ET 495,ET495,EU 4200,EU4200,Hydrochloride, Piribedil,Mesylate, Piribedil,Mono-hydrochloride, Piribedil,Piribedil Mono hydrochloride
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked

Related Publications

R M Post, and R H Gerner, and J S Carman, and J C Gillin, and D C Jimerson, and F K Goodwin, and W E Bunney
January 1986, Clinical neuropharmacology,
R M Post, and R H Gerner, and J S Carman, and J C Gillin, and D C Jimerson, and F K Goodwin, and W E Bunney
December 1974, Clinical pharmacology and therapeutics,
R M Post, and R H Gerner, and J S Carman, and J C Gillin, and D C Jimerson, and F K Goodwin, and W E Bunney
September 1983, Archives of general psychiatry,
R M Post, and R H Gerner, and J S Carman, and J C Gillin, and D C Jimerson, and F K Goodwin, and W E Bunney
January 1980, Communications in psychopharmacology,
R M Post, and R H Gerner, and J S Carman, and J C Gillin, and D C Jimerson, and F K Goodwin, and W E Bunney
December 1986, The American journal of psychiatry,
R M Post, and R H Gerner, and J S Carman, and J C Gillin, and D C Jimerson, and F K Goodwin, and W E Bunney
February 2002, Fundamental & clinical pharmacology,
R M Post, and R H Gerner, and J S Carman, and J C Gillin, and D C Jimerson, and F K Goodwin, and W E Bunney
October 1971, Life sciences. Pt. 1: Physiology and pharmacology,
R M Post, and R H Gerner, and J S Carman, and J C Gillin, and D C Jimerson, and F K Goodwin, and W E Bunney
October 1995, Vision research,
R M Post, and R H Gerner, and J S Carman, and J C Gillin, and D C Jimerson, and F K Goodwin, and W E Bunney
January 1997, Journal of neural transmission (Vienna, Austria : 1996),
R M Post, and R H Gerner, and J S Carman, and J C Gillin, and D C Jimerson, and F K Goodwin, and W E Bunney
January 1983, Progress in neuro-psychopharmacology & biological psychiatry,
Copied contents to your clipboard!